home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The World of Computer Software
/
The World of Computer Software.iso
/
cdc0107.zip
/
CDC1079
< prev
next >
Wrap
Text File
|
1993-01-09
|
3KB
|
42 lines
─ Area: AIDS-HIV - R ─────────────────────────────────────────────────────────
Msg#: 527 Date: 01-08-93 06:03
From: Billi Goldberg Read: Yes Replied: No
To: All Mark:
Subj: (9) CDC SUMMARY 1/7/93
──────────────────────────────────────────────────────────────────────────────
-=> Quoting Billi Goldberg to All <=-
BG> "1993 Nucleoside-Analog Trial Results Expected" AIDS Treatment News
BG> (01/01/93) No. 166, P. 3 (Tate, Larry)
BG> Further developments in the clinical trials of nucleoside-analogs
BG> and combinations of them are expected in 1993. The first development
BG> will be the long-awaited release of data from AIDS Clinical Trials
BG> Group (ACTG) 116A, a study comparing AZT to ddI in people who have
BG> used AZT for fewer than four months. This will compare the two drugs
BG> as a primary therapy and suggest which drug patients starting anti-HIV
BG> therapy should use. It should be known by mid-January whether ddI is
BG> more effective, less effective, or about the same as AZT. Those
BG> participating have T-cell counts less than 300, but the findings
BG> might apply to people starting treatment at all T-cell levels.
BG> Results from the ACTG 019 should be available as early as February, if
BG> not, then by early spring. This trial compared AZT to placebo in
BG> people who started with varying T-cell counts--about half of them
BG> over 500. Information on the group who started with counts over 500
BG> should provide the clearest answer from any U.S. study on the value
BG> of AZT in people in early stages of infection. If AZT delays disease
BG> development in this group, there could for the first time be an
BG> FDA-approved therapy for people with T-cell counts over 500. Another
BG> study, ACTG 155, which compared AZT to a combination of AZT and ddC
BG> in people with fewer than 200 T-cells, will have available data by
BG> late spring. If the findings show an advantage for the combination,
BG> the current label indications for AZT/ddC use may be clarified and
BG> strengthened by the FDA. The trials of 3TC are moving slower.
BG> Currently, it is in late dose-ranging studies and is expected to
BG> begin large Phase II comparative studies in the spring.
BG> -!-
BG> * The GrapeVine/Ferret Face BBS * NLR,ARK * 501-753-8121 DS *
BG> * PostLink(tm) v1.04 GRAPEVINE (#318) : RelayNet(tm) Hub